Phase II study of trabectedin in pretreated patients with advanced colorectal cancer

Clinical Colorectal Cancer

Volumn 6, Issue 7, 2007, Pages 522-528

  Paz Ares, Luis ^a   Rivera Herreros, Fernando ^b   Díaz Rubio, Eduardo ^c   García, Margarita ^d   Casado, Esther ^e   Cubedo, Ricardo ^f   Gravalos, Cristina ^a   Alfaro, Vicente ^g   Gómez, Javier ^g   Izquierdo, Miguel Angel ^g   Tabernero, Josep ^e  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^g PHARMAMAR S A   (Spain)

Author keywords

Antitumor activity; Survival; Toxicity; Transaminases

Indexed keywords

FLUOROURACIL; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; RALTITREXED; TRABECTEDIN; UFT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 34250329180     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2007.n.018     Document Type: Article

References (29)

1. Jimeno JM, Faircloth G, Cameron L, et al. Progress in the acquisition of new marine-derived anticancer compounds: development of ecteinascidin-743 (ET -743). Drugs Future 1996; 21:1155-1165.
2. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999; 42:2493-2497.
3. Minuzzo M, Marchini S, Broggini M, et al. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 2000; 97:6780-6784.
4. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001; 37:97-105.
5. D'Incalci M, Jimeno J. Preclinical and clinical results with the natural marine product ET-743. Expert Opin Investig Drugs 2003; 12:1843-1853.
6. Twelves C, Hoekman K, Bowman A, et al. Phase I and pharmacokinetic study of Yondelis (ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 2003; 39:1842-1851.
7. Taamma A, Misset JL, Riofrio M, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 2001; 19:1256-1265.
8. Villalona-Calero MA, Eckhardt SG, Weiss G, et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res 2002; 8:75-85.
9. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22:890-899.
10. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23:576-584.
11. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22:1480-1490.
12. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005; 23:5484-5492.
13. Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 23:1867-1874.
14. Del Campo J, Roszak A, Ciuleanu T, et al. Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: preliminary results. J Clin Oncol 2006; 24(18 suppl):263s (Abstract #5031).
15. Michaelson MD, Gilligan T, Oh W, et al. Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). J Clin Oncol 2005; 23(16 suppl):382s (Abstract #4517).
16. Gurtler JS, Goldstein L, Delprete S, et al. Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens. J Clin Oncol 2005; 23(16 suppl):34s (Abstract #625).
17. Zelek L, Yovine A, Brain E, et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006; 94:1610-1614.
18. Ghielmini M, Colli E, Erba E, et al. In vitro schedule-dependency of myelotoxicity and cytotoxicity of ecteinascidin 743 (ET-743). Ann Oncol 1998; 9:989-993.
19. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
20. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13:346-353.
21. Takebayashi Y, Goldwasser F, Urasaki Y, et al. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res 2001; 7:185-191.
22. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
23. Giantonio BJ. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings. Semin Oncol 2006; 33(suppl 10):S15-S18.
24. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
25. Lau L, Supko JG, Blaney S, et al. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clin Cancer Res 2005; 11:672-677.
26. Beumer JH, Schellens JH, Beijnen JH. Hepatotoxicity and metabolism of trabectedin: a literature review. Pharmacol Res 2005; 51:391-398.
27. Yver A, Cohen R, Williams D, et al. Assessment of trabectedin (T) induced liver toxicity with correlation to liver morphology in a phase I study of T + pegylated liposomal doxorubicin (PLD). J Clin Oncol 2006; 24(18 suppl):536s (Abstract #9568).
28. van Kesteren C, Twelves C, Bowman A, et al. Clinical pharmacology of the novel marine-derived anticancer agent ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs 2002; 13:381-393.
29. Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001; 7:231-242.